Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03882281
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
- Conditions
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT03883100
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guandong, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation
- Conditions
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT03883087
- Locations
- 🇨🇳
Union Hospital medical college Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Nanfang Hospital of Southern Medical University, Guanzhou, Guangdong, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 230
- Registration Number
- NCT03611868
- Locations
- 🇺🇸
UCLA Hematology & Oncology Clinic, Los Angeles, California, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT03594422
- Locations
- 🇨🇳
Chinese PLA general hospital, Beijing, China, Beijing, China
🇨🇳Guangdong general hospital, Guangzhou, Guangdong, China
🇨🇳Henan cancer hospital, Zhengzhou, Henan, China
APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT03585322
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT03537482
- Locations
- 🇺🇸
Duke Unviersity, Durham, North Carolina, United States
🇺🇸MDACC, Houston, Texas, United States
🇦🇺St. Vincent Hospital, Fitzroy, Victoria, Australia
APG-1252 in Patients With SCLC or Advanced Solid Tumors
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03387332
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT03386526
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸The START Center for Cancer Care, San Antonio, Texas, United States
A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03080311
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸The START Center for Cancer Care, San Antonio, Texas, United States